Spectrum of cisplatin-induced mutations in Escherichia coli.

Publisher Website
Google Scholar
Abstract
Using a forward-mutation assay based on the inactivation of the tetracycline-resistance gene located on plasmid pBR322, we have determined the mutation spectrum induced in Escherichia coli by cisplatin [cis-diamminedichloroplatinum(II)], a widely used antitumor drug. Cisplatin is known to form mainly intrastrand diadducts at ApG and GpG sites. We found that cisplatin efficiently induces mutations in an SOS-dependent way (i.e., dependent upon UV irradiation of the host bacteria). More than 90% of the mutations are single-base-pair substitutions occurring at the potential sites of cisplatin adducts (ApG and GpG). Taking into account the relative proportions of ApG and GpG adducts, we found that the ApG adducts are at lest 5 times more mutagenic than the GpG adducts. Moreover, a strong mutation specificity was seen at the 5'' side of the ApG adducts (A.cntdot.T .fwdarw. T.cntdot.A transversions). The observation that most mutations occur at the 5'' end of adduct at both ApG and GpG sites is discussed in relation to recent structural data.